(Show work and calculations)
Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blue’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017.
BLUE PHARMACEUTICAL INDUSTRIES |
||
Long-term debt | ||
Notes payable, 9% |
$980,000 |
|
8% convertible bonds payable |
4,960,000 |
|
9% bonds payable |
5,940,000 |
|
Total long-term debt |
$11,880,000 |
|
Shareholders’ equity | ||
Preferred stock, 6% cumulative, $50 par value, 105,000 shares authorized, 26,250 shares issued and outstanding |
$1,312,500 |
|
Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding |
980,000 |
|
Additional paid-in capital |
4,020,000 |
|
Retained earnings |
5,930,000 |
|
Total shareholders’ equity |
$12,242,500 |
The following transactions have also occurred at Blue.
1. | Options were granted on July 1, 2016, to purchase 220,000 shares at $16 per share. Although no options were exercised during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share. | |
2. | Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016. | |
3. | The preferred stock was issued in 2016. | |
4. | There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017. | |
5. | The 980,000 shares of common stock were outstanding for the entire 2017 fiscal year. | |
6. | Net income for fiscal year 2017 was $1,510,000, and the average income tax rate is 40%. |
For the fiscal year ended June 30, 2017, calculate the following
for Blue Pharmaceutical Industries. (Round answers to 2
decimal places, e.g. $2.45.)
(a) Basic earnings per share.
(b) Diluted earnings per share.
Net income after tax | 1,510,000 |
Less: dividend to preferred stock (1312500*6%) | 78,750 |
Net income available for common stock holders | 1,431,250 |
Net income available for common stock holders | 1,431,250 |
Divided by: weighted average share in common stock | 980,000 |
Basic earnings per share | $ 1.4605 |
Stock options | |
Market value of option exercisable (220000*20) | 4,400,000 |
Less: exercisable value of option (220000*16) | 3,520,000 |
Value of option | 880,000 |
Number of share adjusted (880000/20) | 44,000 |
Convertible bond | |
Interest paid to bond (4960000*8%) | 396,800 |
Less: tax on interest (396800*40%) | 158,720 |
Adjustment in income for convertible bond | 238,080 |
Conversion ratio | 50 |
Multiply by: Number of bond (4960000/1000) | 4,960 |
Number of share adjusted | 248,000 |
Convertible preferred stock | |
There is No Convertible preferred stock |
Instruments | Increase in earning | Increase in number of common shares | Earning per incremental share (Increase in earning / increase in number of common shares) |
Options | 0 | 44,000 | 0.00 |
Convertible bond | 238,080 | 248,000 | 0.96 |
The order in which to include dilutive instruments (lowest Earning per incremental share considered First.) | |
1 | Options |
2 | Convertible bond |
Dilutive Earning per share | ||||
Adjusted Net income | Potential common share | Per share (Adjusted Net income / potential common share) | Nature | |
As per Basic Earning per share | 1,431,250 | 980,000 | $ 1.4605 | |
Add: options | 0 | 44,000 | Dilutive | |
1,431,250 | 1,024,000 | $ 1.3977 | ||
Add: Convertible bond | 238,080 | 248,000 | Dilutive | |
1,669,330 | 1,272,000 | $ 1.3124 |
Reported under financial statement | |
Basic earnings per share | $ 1.46 |
Diluted Earnings per share | $ 1.31 |
(Show work and calculations) Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently...
Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Oriole’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Oriole Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 9% $980,000 8% convertible bonds payable 4,960,000 9% bonds payable 5,940,000 Total long-term debt $11,880,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Problem 16-5 Amy Dyken, controller at Flint Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Flint's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. FLINT PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable $990,000 4,920,000 6,000,000 Total long-term debt $11,910,000 Shareholders' equity Preferred stock, 6% cumulative,...
Amy Dyken, controller at Pina Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Pina’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. PINA PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,950,000 Total long-term debt $12,000,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Metlock Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Metlock's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017 METLOCK PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable $1,020,000 5,080,000 6,110,000 $12,210,000 Total long-term debt Shareholders' equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,990,000 Total long-term debt $12,030,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan financial statements Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term diebt Notes payable, 10% 9X convertible bonds payable 10% bonds payable Total long-term debt $1.000.000 5,050,000 5.920,000 $11.970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Monty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Monty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% 8% convertible bonds payable 11% bonds payable Total long-term debt $980,000 5,030,000 6,100,000 $12,110,000 Shareholders' equity Preferred stock, 6% cumulative,...
Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% $1,020,000 9% convertible bonds payable 5,020,000 11% bonds payable 6,120,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...